Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica A Slavin

Showing results (11-20 of 281) with videos related to

Pageof 29
Sort By:
Leukemia & Lymphoma|October 6, 2012
Fluoroquinolone prophylaxis: worth the cost?Gabrielle M Haeusler, Monica A Slavin
Leukemia & Lymphoma|November 30, 2013
More than a feeling: new approach required for assessing immunosuppressionBenjamin W Teh, Monica A Slavin
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 2, 2026
Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing WorldAbby P Douglas, Monica A Slavin
Blood Reviews|December 3, 2008
Bloodstream infections in haematology: risks and new challenges for preventionLeon J Worth, Monica A Slavin
Lancet (London, England)|December 20, 2015
Isavuconazole: a role for the newest broad-spectrum triazoleMonica A Slavin, Karin A Thursky
The Lancet. Haematology|December 24, 2023
Extended duration of letermovir prophylaxis: how long is long enough?Abby P Douglas, Monica A Slavin
Leukemia & Lymphoma|February 25, 2012
Staphylococcus aureus meningitis: barriers to treatmentBenjamin W Teh, Monica A Slavin
Leukemia & Lymphoma|June 3, 2017
Cart before the horse: use of Aspergillus PCR to increase the diagnostic yield from BAL in hematological patients at risk of invasive aspergillosisOlivia Catherine Smibert, Monica A Slavin
Leukemia & Lymphoma|June 20, 2015
Improving the outcome of bloodstream infection in patients with hematological malignancies: looking beyond antibioticsMonica A Slavin, Karin A Thursky
Blood Advances|December 1, 2025
Reporting infections in cellular therapiesGemma K Reynolds, Monica A Slavin
Pageof 29

Showing results (11-20 of 281) with videos related to

Sort By:
Pageof 29
Leukemia & Lymphoma|October 6, 2012
Fluoroquinolone prophylaxis: worth the cost?Gabrielle M Haeusler, Monica A Slavin
Leukemia & Lymphoma|November 30, 2013
More than a feeling: new approach required for assessing immunosuppressionBenjamin W Teh, Monica A Slavin
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 2, 2026
Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing WorldAbby P Douglas, Monica A Slavin
Blood Reviews|December 3, 2008
Bloodstream infections in haematology: risks and new challenges for preventionLeon J Worth, Monica A Slavin
Lancet (London, England)|December 20, 2015
Isavuconazole: a role for the newest broad-spectrum triazoleMonica A Slavin, Karin A Thursky
The Lancet. Haematology|December 24, 2023
Extended duration of letermovir prophylaxis: how long is long enough?Abby P Douglas, Monica A Slavin
Leukemia & Lymphoma|February 25, 2012
Staphylococcus aureus meningitis: barriers to treatmentBenjamin W Teh, Monica A Slavin
Leukemia & Lymphoma|June 3, 2017
Cart before the horse: use of Aspergillus PCR to increase the diagnostic yield from BAL in hematological patients at risk of invasive aspergillosisOlivia Catherine Smibert, Monica A Slavin
Leukemia & Lymphoma|June 20, 2015
Improving the outcome of bloodstream infection in patients with hematological malignancies: looking beyond antibioticsMonica A Slavin, Karin A Thursky
Blood Advances|December 1, 2025
Reporting infections in cellular therapiesGemma K Reynolds, Monica A Slavin
Pageof 29